Register for this webinar - FREE for IPEC-Americas members, $59.00 for non-members. Not sure if your company is an IPEC-Americas member? Check here!
The webinar was originally recorded on February 14, 2018. The concepts of what should be included in Quality Agreements have been explained in the 2009 IPEC Quality Agreement Guide and Templates. However, with new regulatory requirements and more complex supply chains, the Guide was recently revised by a team of IPEC experts to provide practical and detailed guidance on how to meet current challenges.
- Familiarize yourself with appropriate content of an excipient Quality Agreement
- Understand the major changes to the guide revision
- Familiarize yourself with the contents of the Quality Agreement Templates
- Understand the innovative concept of Manufacturer’s Quality Statement template
Bretta Lichtenhan is Head of Pharma Registrations within the Regulatory organization of the Life Science division of MilliporeSigma. She manages a global team of regulatory experts, focused on regulatory registration of products such as excipients, active pharmaceutical ingredients (APIs), highly potent APIs, linkers, antibodies & antibody-drug conjugates, and pharmaceutical materials for the (bio-) pharmaceutical industry. She is currently Chair-Elect of IPEC-America’s and has previously held roles within the association such as Vice Chair of Administrative affairs and chair of the Excipient Qualification Committee. Bretta has also been actively involved in the planning of ExcipientFest Americas (now Excipient World), for the last several years. She has over 21 years of experience in the industry with previous experience at Biopharma companies Genzyme (a Sanofi Company) and Percivia LLC. Bretta has worked for MilliporeSigma for over 10 years in various roles from R&D Product Development, Product Management, Regulatory Affairs and Business Development. Bretta has a bachelor’s degree in Biology from the University of New Hampshire and Master of Biotechnology Engineering from Tufts University.